Director Noubar Afeyan buys $75 million of Generate Biomedicines, Inc. (GENB)

Noubar Afeyan, director of Generate Biomedicines, Inc., bought 4,687,500 shares on the open market on March 2, 2026 at an average of $16.00 a share, for a total of $75 million. The purchase was reported to the SEC on Form 4 on March 2, 2026.

It is a new position: the filing shows no shares held directly before this purchase.

3 other insiders also bought at least $10,000 of GENB within 30 days, which makes this a cluster buy.

In the 12 months up to this filing, Generate Biomedicines, Inc. insiders reported 5 open-market purchases and 0 sales.

WallStPal Score: 62 out of 100, because of a brand-new position; a large purchase; 3 other insiders also bought.

What happened next: after 1 month the stock was down 16.8% (9.2 points worse than the S&P 500); after 3 months the stock was down 25.2% (35.5 points worse than the S&P 500); after 6 months the stock was down 4.2% (16.4 points worse than the S&P 500). Based on weekly prices from the week of the purchase.

Our read

This one purchase is 50% of all insider buying at GENB in the past year, the first open-market purchase by Noubar Afeyan in our records. It is worth reading next to the company's own results and news before drawing conclusions.

Source: SEC Form 4 filing ↗. This story was written automatically from the filing and weekly price data. Information, not investment advice.

Examples

Big insider purchases have made news before. In January 2016, with bank stocks falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares, about $26 million of his own money, and the purchase was widely reported as a sign of confidence.

Explain it like I'm 13

Noubar Afeyan helps run Generate Biomedicines, Inc.. Spending $75 million of their own money on the company's stock is like a coach buying a big stack of tickets to their own team's games: it suggests they think the team will do well. It is not a promise, and insiders can be wrong.

More: all GENB insider trades · Noubar Afeyan's track record